PMID- 34621322
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - YiQi YangYin Decoction Attenuates Nonalcoholic Fatty Liver Disease in Type 2 
      Diabetes Rats.
PG  - 5511019
LID - 10.1155/2021/5511019 [doi]
LID - 5511019
AB  - BACKGROUND: YiQi YangYin Decoction (YQ) is a modern Chinese formula composed by 
      the guidance of traditional Chinese medicine theory, which consists of nine 
      traditional Chinese medicines and is applied to treat type 2 diabetes mellitus 
      (T2DM) with nonalcoholic fatty liver in clinic in China for more than a decade. 
      This study aims to evaluate the antidiabetes and lipid-lowering effect of YQ and 
      explore the possible mechanisms of this action. METHODS: T2DM rat models were 
      established and given YQ at three different doses for three weeks. Tissues, 
      including pancreas islet and liver, and blood serum were collected. The levels of 
      fasting blood glucose (FBG), fasting insulin (Fins), lipid index, such as total 
      cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and 
      low-density lipoprotein (LDL), and hepatic function index such as alanine 
      aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline 
      phosphatase (ALP) in serum were measured. Pancreas islet damage and liver damage 
      were observed by hematoxylin and eosin staining. The glycogen content and lipid 
      accumulation in liver were determined by periodic acid-Schiff (PAS) staining and 
      Oil Red O staining. The expression levels of insulin receptor substrate 2 
      (IRS-2), phosphatidylinositol 3 kinase-associated p85alpha (PI3K p85alpha), AKT, and 
      Glucose Transporter 2 (Glut4) in pancreas islet and AMP-activated protein kinase 
      alpha (AMPKalpha), sterol regulatory element-binding protein 1c (SREBP1c), acetyl-CoA 
      carboxylase (ACC1), and peroxisome proliferator-activated receptor-alpha (PPARalpha) in 
      liver were determined by western blotting. The relative expressions of ACC1, 
      fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD1), carnitine palmityl 
      transferase-1 (CPT-1), and SREBP-1 mRNA were detected by qRT-PCR. RESULTS: After 
      administering YiQi for three weeks, the levels of fast blood glucose, fasting 
      insulin, TC, TG, LDL, ALT, AST, and ALP were significantly decreased, while HDL 
      significantly increased compared with the model group. YQ could obviously 
      attenuate pancreatic damage and improve islet alpha- and ss-cell survival compared 
      with the model group. Furthermore, YQ could attenuate hepatic damage caused by 
      lipid accumulation, decrease the content of lipid, and increase the hepatic 
      glycogen content, compared with the model group. In addition, YQ remarkably 
      elevated the proteins expression of p-PI3K, p-AKT, and GLUT4 in pancreas islet 
      and elevated the proteins expression of p-PI3K, p-AKT, GLUT4, p-AMPK, SREBP1, and 
      PPARalpha and inhibited the expression of p-ACC1 in liver. Besides, YQ reduced the 
      relative expression of ACC1, FAS, SERBP-1c, and SCD mRNA along with the decreased 
      production of CPT-1 mRNA. CONCLUSIONS: YQ could attenuate type 2 diabetes 
      mellitus by improving islet alpha- and ss-cells via IRS-2/AKT/GLUT4 pathway and 
      nonalcoholic fatty liver by ameliorating lipid accumulation via 
      AMPK/PPARalpha/SREBP1/ACC1 pathway.
CI  - Copyright (c) 2021 Fengjin Li et al.
FAU - Li, Fengjin
AU  - Li F
AD  - The Heilongjiang University of Chinese Medicine, Harbin 150040, China.
AD  - Heilongjiang Academy of Traditional Chinese Medicine, Harbin 150036, China.
FAU - Liu, Genli
AU  - Liu G
AD  - The Heilongjiang University of Chinese Medicine, Harbin 150040, China.
FAU - Xue, Piliang
AU  - Xue P
AD  - The Heilongjiang University of Chinese Medicine, Harbin 150040, China.
AD  - Heilongjiang Academy of Traditional Chinese Medicine, Harbin 150036, China.
FAU - Ren, Zhen
AU  - Ren Z
AD  - The Heilongjiang University of Chinese Medicine, Harbin 150040, China.
FAU - Dai, Peifang
AU  - Dai P
AD  - The Heilongjiang University of Chinese Medicine, Harbin 150040, China.
FAU - Niu, Wenying
AU  - Niu W
AUID- ORCID: 0000-0001-6105-9266
AD  - The Heilongjiang University of Chinese Medicine, Harbin 150040, China.
FAU - Xin, Mu
AU  - Xin M
AUID- ORCID: 0000-0001-8459-5897
AD  - The Heilongjiang University of Chinese Medicine, Harbin 150040, China.
LA  - eng
PT  - Journal Article
DEP - 20210928
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8492297
COIS- The authors declare no conflicts of interest.
EDAT- 2021/10/09 06:00
MHDA- 2021/10/09 06:01
PMCR- 2021/09/28
CRDT- 2021/10/08 07:08
PHST- 2021/03/01 00:00 [received]
PHST- 2021/06/16 00:00 [revised]
PHST- 2021/08/31 00:00 [accepted]
PHST- 2021/10/08 07:08 [entrez]
PHST- 2021/10/09 06:00 [pubmed]
PHST- 2021/10/09 06:01 [medline]
PHST- 2021/09/28 00:00 [pmc-release]
AID - 10.1155/2021/5511019 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Sep 28;2021:5511019. doi: 
      10.1155/2021/5511019. eCollection 2021.